Question-and-Answer Session
Operator
(Operator Instructions). First question comes from the line of Mark Monane of Needham & Company.
Mark Monane - Needham & Company
Thanks for taking our questions. Congratulations on your progress, a very exciting way to start the week.
Peter Lawrence
Thank you, Mark.
Mark Monane - Needham & Company
I'm at the American Heart Association meeting where there is lot of talk about biomarkers. We saw some data on this, the high-sensitivity-CRP.
Can you comment, is your potential in these trials are coming up, especially the lung cancer trial that you're planning, to look at any biomarkers that may have given us an indication of either which patients maybe most responsible or maybe to outline the program outcomes? Is there a good outcome before we actually see a survival of PFS outcome?
Paolo Pucci
Thank you for the question, Mark. I think the most proper person to answer this is Tom Chan who has been in charge of the pre-clinical programs and is in charge of biomarkers program here at ArQule. Tom, please?
Thomas Chan
Thank you, Paolo. With full cooperation of Brian Schwartz and the clinical team for every single patients coming into lung cancer study, we have agreement from them to supply us with both diagnostic block and to extend possible biopsy tissues. We'll have to understand the biomarker status of each of these patients.
So, I would say by the end of this trial, we'll have a very good understanding on both predictive biomarker as well as pharmacodynamic biomarker.
Paolo Pucci
And now with that better understanding of biomarkers across our entire pipeline. So not just for 197, but also on the other assets that we hope we'll make emerge over the next year or two is a priority.
Mark Monane - Needham & Company
Concerning biomarkers in lung cancer, we've had some recent information about KRAS mutation and EGFR mutations. Can you comment how you might work that information into either designing a protocol of patient selection for the lung cancer trial that you're designing?
Brian Schwartz
I'll take that question Mark. It's Brian Schwartz here. In our trial, as Tom mentioned, we will be looking at KRAS status, EGFR and Met status of all patients coming in. There is a body of data emerging and hopefully we will able to better understand which patients will benefit from ARQ 197 class and EGFR inhibitor, understanding the patients that come in.
- To read the full transcript on Seeking Alpha, click here »
